Table 2.

Mean and ± SEM sample data for the two centre cohorts used for the biomarker discovery and validation cohorts

Biomarker discovery cohort	Control n = 15	LBD n = 10
Gender (M:F)	5:10	6:4
Mean Age at Sampling (yrs ± SD)	61 ± 9.9	71.9 ± 4.3
Median disease duration (yrs ± SD)	n/a	3.4 ± 1.57
Mean Aβ42 levels (pg/ml ± SD)	905.41 ± 237	695.6 ± 330.7
Mean h-tau levels (pg/ml ± SD)	136.58 ± 162	523 ± 432
Mean p-tau181 levels (pg/ml ± SD)	19.33 ± 11.11	52 ± 39
Validation cohort	Control n = 15	LBD n = 17	PD n = 7	AD n = 16
Gender (M:F)	5:10	10:7	5:2	6:10
Mean Age at Sampling (yrs ± SD)	61 ± 9.9	72.1 ± 5.5	68.1 ± 3.4	78.1 ± 6.67
Median disease duration (yrs ± SD)		3.3 ± 1.9	4.1 ± 2.78
Mean Aβ42 levels (pg/ml ± SD)	905.41 ± 237	663.5 ± 268	886.4 ± 232	503.68 ± 165.88
Mean h-tau levels (pg/ml ± SD)	136.58 ± 162	679 ± 673	139 ± 93	733.77 ± 481.25
Mean p-tau levels (pg/ml ± SD)	19.33 ± 11.11	64.5 ± 48.8	26 ± 11	93.38 ± 31.55

Control, LBD, PD and 7 AD samples were received from centre 1 and 9 AD samples from centre 2. As the two centres share the same clinical workup for AD the data in Table 2 has been combined